Patents Assigned to LG Life Sciences, Ltd.
-
Publication number: 20170253588Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.Type: ApplicationFiled: January 20, 2017Publication date: September 7, 2017Applicant: LG LIFE SCIENCES, LTD.Inventors: Ae Ri Kim, Jin Hwa Lee, Ki Sook Park, Jong Ryoo Choi, Tae Hee Lee, Jay Hyok Chang, Do Hyun Nam, Hoon Choi
-
Publication number: 20170165272Abstract: The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effectType: ApplicationFiled: February 24, 2017Publication date: June 15, 2017Applicant: LG LIFE SCIENCES LTD.Inventors: Soon Ha KIM, Hyoung Jin KIM, Heui Sul PARK, Seon Yeong GU, Hyo Shin KWAK, Du Hee PARK, Hyo Soo KIM, Hyun Jai CHO, Ji Hyun KIM, Ju Young KIM, Kwang Min PARK
-
Publication number: 20170035776Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (Tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating NAFLD, and in particular, NASH.Type: ApplicationFiled: April 17, 2015Publication date: February 9, 2017Applicant: LG LIFE SCIENCES LTD.Inventors: Soon Ha KIM, Hyoung Jin KIM, Heui Sul PARK, Seo Hyun AHN, Min Ho SHONG, Hyo Kyun CHUNG
-
Patent number: 9540362Abstract: The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders.Type: GrantFiled: February 19, 2014Date of Patent: January 10, 2017Assignee: LG LIFE SCIENCES LTD.Inventors: Seung Yup Paek, Sung Bae Lee, Deok Seong Park, Won Hyung Lee
-
Patent number: 9447044Abstract: The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.Type: GrantFiled: November 5, 2013Date of Patent: September 20, 2016Assignee: LG LIFE SCIENCES LTD.Inventors: Young Kwan Kim, Myoung Yeol Kim, Sang Yun Park, Ok Ku Park, Vasily Artemov, Sang Dae Lee, Hyun Woo Joo, Eun Sil Choi
-
Publication number: 20160264569Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.Type: ApplicationFiled: January 15, 2016Publication date: September 15, 2016Applicant: LG LIFE SCIENCES, LTD.Inventors: Ae Ri Kim, Jin Hwa Lee, Ki Sook Park, Jong Ryoo Choi, Tae Hee Lee, Jay Hyok Chang, Do Hyun Nam, Hoon Choi
-
Publication number: 20160243242Abstract: Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time.Type: ApplicationFiled: May 4, 2016Publication date: August 25, 2016Applicant: LG Life Sciences, Ltd.Inventors: Suk Young CHOI, Hoon Sung JEH
-
Publication number: 20160200709Abstract: The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.Type: ApplicationFiled: August 21, 2014Publication date: July 14, 2016Applicant: LG LIFE SCIENCES LTD.Inventors: Heui Sul PARK, Sun Young KOO, Hyoung Jin KIM, Sung Bae LEE, Hyo Shin KWAK, Vasily ARTEMOV, Soon Ha KIM
-
Publication number: 20160194313Abstract: The present invention relates to an indole amide compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.Type: ApplicationFiled: August 21, 2014Publication date: July 7, 2016Applicant: LG LIFE SCIENCES LTD.Inventors: Heui Sul PARK, Sun Young KOO, Hyoung Jin KIM, Sung Bae LEE, Hyo Shin KWAK, Seung Yup PAEK, Soon Ha KIM
-
Publication number: 20160168096Abstract: The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.Type: ApplicationFiled: June 26, 2014Publication date: June 16, 2016Applicant: LG LIFE SCIENCES LTD.Inventors: Young Kwan KIM, Sang Yun PARK, Hyun Woo JOO, Eun Sil CHOI
-
Publication number: 20160051558Abstract: The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.Type: ApplicationFiled: March 25, 2014Publication date: February 25, 2016Applicant: LG LIFE SCIENCES LTD.Inventors: Seok Goo CHO, Na Youn KIM, Eun Jung KIM, Keon Il IM, Jung Yeon LIM, Eun Joo JEON
-
Publication number: 20160045497Abstract: The present invention relates to a pharmaceutical composition including valsartan and rosuvastatin calcium as active ingredients, and a manufacturing method therefor. The pharmaceutical composition including valsartan and rosuvastatin calcium according to the present invention can alleviate side effects of the existing single preparations and simultaneously improve compliance of patients having a cardiovascular disease, a hyperlipidemic disease and a complex disease thereof, and increases treatment and prevention effects, and in particular, obtains synergistic effects in treating hyperlipidemia, and enhances the dissolution rate of valsartan and rosuvastatin calcium and treatment effects by granulating valsartan and mixing rosuvastatin calcium.Type: ApplicationFiled: March 11, 2014Publication date: February 18, 2016Applicant: LG LIFE SCIENCES LTD.Inventors: Jeong Uk SONG, Geun Tae KIM, Sun Il KIM, Ki Kon LEE
-
Patent number: 9234211Abstract: The present invention relates to a hybrid promoter, in which a whole or a part of a CMV enhancer, a whole or a part of a ?-actin promoter, a whole or a part of a CMV promoter, and a whole or a part of a ?-actin intron are operably linked to each other, a recombinant vector comprising the same, a transformant transformed with the recombinant vector, a pharmaceutical composition comprising the recombinant vector or the transformant, and a method for preparing a target protein using the recombinant vector or the transformant. The hybrid promoter of the present invention is able to induce high expression of a target protein in a eukaryotic cell. Therefore, the hybrid promoter of the present invention can be effectively used for the development of an antibody or the production of a DNA vaccine.Type: GrantFiled: November 29, 2011Date of Patent: January 12, 2016Assignee: LG Life Sciences Ltd.Inventors: Yeon Chul Kim, Saem Jung, Jun Jung
-
Publication number: 20150376173Abstract: The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders.Type: ApplicationFiled: February 19, 2014Publication date: December 31, 2015Applicant: LG LIFE SCIENCES LTD.Inventors: Seung Yup PAEK, Sung Bae LEE, Deok Seong PARK, Won Hyung LEE
-
Publication number: 20150309063Abstract: According to the present invention, an automatic in vitro diagnosis apparatus including an inclined rotating stirrer is an apparatus for the automatic in vitro diagnosis of a clinical specimen or a reagent. The present invention includes: a clinical specimen storage unit which stores a clinical specimen; a reagent storage unit which stores a reagent; a code reader unit which recognizes an identification code attached to the clinical specimen storage unit or to the reagent storage unit; a dispenser which suctions the clinical specimen and the reagent from the clinical specimen storage unit and the reagent storage unit, and transports the clinical specimen and the reagent which are suctioned; and a rotating stirrer which receives the clinical specimen and the reagent from the dispenser and rotates about an axis of rotation so as to stir the clinical specimen and the reagent.Type: ApplicationFiled: November 26, 2013Publication date: October 29, 2015Applicant: LG LIFE SCIENCES LTD.Inventors: Jae Hoon OH, Moon Kyu PARK, Seong Wook KIM, Joon Hee LEE
-
Patent number: 9161981Abstract: Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative.Type: GrantFiled: September 9, 2011Date of Patent: October 20, 2015Assignee: LG LIFE SCIENCES, LTD.Inventors: Jin Eon So, Dong Jun Yeo, Yoon-Seon Jang
-
Publication number: 20150291585Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.Type: ApplicationFiled: February 13, 2015Publication date: October 15, 2015Applicant: LG Life Sciences, LTDInventors: Ae Ri Kim, Jin Hwa Lee, Ki Sook Park, Jong Ryoo Choi, Tae Hee Lee, Jay Hyok Chang, Do Hyun Nam, Hoon Choi
-
Publication number: 20150291527Abstract: The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.Type: ApplicationFiled: November 5, 2013Publication date: October 15, 2015Applicant: LG LIFE SCIENCES LTD.Inventors: Young Kwan Kim, Myoung Yeol Kim, Sang Yun Park, Ok Ku Park, Vasily Artemov, Sang Dae Lee, Hyun Woo Joo, Eun Sil Choi
-
Patent number: 9091720Abstract: Provided is a detection system using a magnetic resistance sensor. The detection system includes a magnetic resistance sensor for detecting a magnetic element of a specimen containing a magnetic particle. An external magnetic-field application device applies external magnetic fields to the magnetic resistance sensor in first and second directions, and has a space for entrance or exit of a specimen holding unit. A horizontal drive module receives the specimen holding unit to horizontally move the specimen holding unit under the magnetic resistance sensor. A vertical drive module receives the magnetic resistance sensor to vertically move the magnetic resistance sensor to the specimen holding unit.Type: GrantFiled: August 19, 2011Date of Patent: July 28, 2015Assignee: LG LIFE SCIENCES LTD.Inventors: Jong Won Park, Chung Wan Lee, Jeong Ryul Kim
-
Patent number: 9000028Abstract: The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.Type: GrantFiled: April 9, 2013Date of Patent: April 7, 2015Assignee: LG Life Sciences Ltd.Inventors: Soon Ha Kim, Hyoung Jin Kim, Sun Young Koo, Chul Woong Chung, Sung Bae Lee, Heui Sul Park, Seung Hyun Yoon, Hyo Shin Kwak, Dong Ook Seo, Eok Park